

# Swedish Biomimetics 3000® AB

A V<sup>2</sup>IO® Innovation Accelerator

## PRESS RELEASE

Stockholm, 11<sup>th</sup> October 2013

### Swedish Biomimetics 3000® and University of East Anglia nominated for The Times Higher Education 2013 “Outstanding Contribution to Innovation & Technology Award”, in London.

Prescribing medicines today is based on a One-Size-Fits-All principle. However, it is estimated that 50% of the prescribed drugs are not effective due to genetic variations inherent in the patient population. This leads to suboptimal treatments, resulting in unwanted side effects both of which negatively impact the patient and healthcare budgets. Global cancer treatment costs are in the region of USD 1 trillion, of which only (at best) 20% are effective. Eradicating this waste drives the search for an effective Personalised Medicine strategy, as indicated by the UK's TSB recent funding stream dedicated to stratified and personalised medicine. A consortium comprising of the University of East Anglia (UEA) and Swedish Biomimetics 3000® Ltd (SB3000) is developing a technology to determine, develop and manufacture small volumes of peptide/oligonucleotide based medicines, personalised to an individual's needs, at reasonable costs.  $\mu$ Lot® is a radically new, bio-inspired, platform technology, combining a front-end ontology system to accelerate the determination of the optimal drug structure starting point. Which then leads into the accelerated synthesis and testing cycle, ultimately leading to the manufacturing of the best drug for the patient at accessible costs.

$\mu$ Lot® is based on a mass customisation, assembly-line thinking and it is inspired by the most fundamental of biological processes: the transcription of RNA into proteins by ribosomes.  $\mu$ Lot® has at its core the continuous manufacturing of small 'lots' of therapeutics - initially peptides and oligonucleotides as excellent candidates for personalized medicines and/or for diseases for which there are currently no/or sufficient therapies. This contrasts with the current R&D batch methodology using serial manufacturing and test sequences to create/test/modify/test structural variations. Such methods are time consuming, expensive, and have a significant environmental impact, which ultimately drive up the economic 'Cost of Goods' - and can prohibit such therapeutics becoming publicly available. The development of  $\mu$ Lot® is multidisciplinary, created by collaboration amongst biologists, chemists, engineers and industry, working within a unique biomimetic business environment designed to accelerate the translation of biological concepts into commercially viable innovations. The consortium between UEA and Swedish Biomimetics 3000® Ltd have applied the V<sup>2</sup>IO® innovation acceleration model, which manages the 'intersectional engagement' of all disciplines needed to deliver the vision.

The Times Higher Education Award Event is an annual recognition of University Excellence and of Outstanding Achievements. The 2013 Awards is in their ninth year and are the highlight of the academic calendar and a celebration of the best in the UK higher education. The Awards ceremony will take place on Thursday 28<sup>th</sup> November at the Grosvenor House Hotel Park Lane, London. There are 18 categories and the Consortium comprising of the University of East Anglia (UEA) and Swedish Biomimetics 3000® are among 6 nominees for the Category “Outstanding Contribution to Innovation and Technology”. This Award recognizes and promotes technological breakthroughs at institutions, teams or individuals in the UK, in either products or services that have the potential to significantly enhance the operations of the commercial or the public sector.

#### About Swedish Biomimetics 3000®

Swedish Biomimetics 3000® was founded 2004 in Sweden and 2007 in the UK by the Swedish entrepreneur Lars Uno Larsson. The mission is to fund and through its V<sup>2</sup>IO® innovation accelerating model, foster translational research and development of Biomimetics inspired



## Swedish Biomimetics 3000® AB

A V<sup>2</sup>IO® Innovation Accelerator

concepts until they are considered commercial candidates. Swedish Biomimetics 3000® with its corporate office in Stockholm, Sweden, has virtual offices at Medicon Village in Lund, Japan, USA, Australia and a fully owned research/development and commercial subsidiary, Swedish Biomimetics 3000® Ltd at Oxford Science Park, UK. Swedish Biomimetics 3000® Ltd and University of Leeds received 2011 The Times Higher Education “Outstanding Contribution to Innovation and Technology Award” for its development of the  $\mu$ Mist® spray platform technology inspired by the Bombardier Beetle`s defense mechanism.

For further information contact Andrew J Copestake, CEO, phone +44 7545 899412.

<http://www.swedishbiomimetics3000.com>

### About UEA - Fifty Years of the University of East Anglia

The University of East Anglia (UEA) was founded in 1963 and this year celebrates its 50th anniversary. It has played a significant role in advancing human understanding and in 2012 the Times Higher Education ranked UEA as one of the 10 best universities in the world under 50 years of age. The university has graduated more than 100,000 students, attracted to Norwich Research Park some of Britain’s key research institutes and a major University Hospital, and made a powerful cultural, social and economic impact on the region.

[www.uea.ac.uk/50years](http://www.uea.ac.uk/50years)